DOI · e01.org

Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience

Keita Ogawa, Hiroaki Kanzaki, Tetsuhiro Chiba, Junjie Ao, Na Qiang, Yaojia Ma, Jiaqi Zhang, Sae Yumita, Takamasa Ishino, Hidemi Unozawa, Motoyasu Kan, Terunao Iwanaga, Miyuki Nakagawa, Kisako Fujiwara, Naoto Fujita, Takafumi Sakuma, Keisuke Koroki, Yuko Kusakabe, Kazufumi Kobayashi, Naoya Kanogawa · Journal of Cancer · 2022

  • DOI 10.7150/jca.71494
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2022

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2022

Abstract

Atezolizumab plus bevacizumab (ATZ/BV) treatment is a combined immunotherapy consisting of immune checkpoint inhibitor (ICI) and anti-vascular endothelial growth factor monoclonal antibody, which has brought a major paradigm shift in the treatment of unresectable hepatocellular carcinoma (HCC).Gain-of-function mutation of CTNNB1 contributes to resistance of ICI monotherapy through the framework of non-T-cell-inflamed tumor microenvironment.However, whether CTNNB1 mutation renders resistance to ATZ/BV similar to ICI monotherapy remains to be elucidated.In this study, a liquid biopsy sample in plasma of 33 patients with HCC treated with ATZ/BV was subjected to droplet digital PCR for detecting hotspot mutations at the exon 3 of CTNNB1 locus.A total of eight patients (24.2%) exhibited at least one CTNNB1 mutation.The objective response rate (ORR) in patients with wild-type (WT) and mutant (MT) CTNNB1 was 8.0% and 12.5%, respectively, and the disease control rate (DCR) was 68.0% and 87.5%, respectively.No significant difference in both ORR and DCR has been observed between the two groups.The median progression-free survival in patients with WT and MT CTNNB1 was 6.6 and 7.6 months, respectively (not statistically significant).Similarly, no significant difference in overall survival has been observed between patients with WT and MT CTNNB1 (13.6 vs.

12.3 months).In conclusion, the treatment effect of ATZ/BV in patients with HCC with MT CTNNB1 was comparable to those patients with WT CTNNB1.These results implicate that BV added to ATZ might improve immunosuppressive tumor microenvironment caused by CTNNB1 mutation.

Open the resolved locator · 10.7150/jca.71494

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:03 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v13p2656.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.